Abstract:
Resveratrol (RES) has a low bioavailability. This limitation was addressed in an earlier
review and several recommendations were offered. A literature search was conducted in order to
determine the extent of the research that was conducted in line with these recommendations, along
with new developments in this field. Most of the identified studies were pre-clinical and confirmed
the heightened activity of RES analogues compared to their parent compound. Although this has
provided additional scientific kudos for these compounds and has strengthened their potential to
be developed into phytopharmaceutical products, clinical trials designed to confirm this increased
activity remain lacking and are warranted.
